New Variants of SARS-CoV-2 and Next Generation of COVID-19 Treatments was written by Khiali, Sajad;Entezari-Maleki, Taher. And the article was included in Journal of Clinical Pharmacology in 2022.Application In Synthesis of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate The following contents are mentioned in the article:
Almost 2 years into the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of cases of coronavirus disease 2019 (COVID-19), morbidity, and mortality are still increasing. Inspite of the considerable progress in the development of the COVID-19 vaccines, adequate vaccination cover age has not been achieved even in the most developed countries, and a significant gap still exists among high-,middle, and low-income countries. The assessment of the neutralization efficiency of the BNT162b2(Pfizer-BioNTech) COVID-19 vaccine against different variants showed that neutralization against the omicron variant is lower compared with the previous variants of concern, even after the third dose of vaccine. Accordingly, evaluation of the effectiveness of 2 doses of BNT162b2 (Pfizer-BioNTech) or ChAdOx1 nCoV-19 (AstraZeneca) COVID-19 vaccines showed limited protection against symptomatic disease caused by the omicron variant. Effective mAbs Against the Omicron Variant. Effective Antivirals Against the Omicron Variant. Next Generation of COVID-19 Treatments. In conclusion, given emerging of new variants of SARS-CoV-2, along with the development of effective vaccines against new variants, the future of COVID-19 medications will belong to the drugs that are resistant to the virus mutation with an appropriate safety profile. The focus of manufacturers should be on the development of drugs that are resistant to the virus mutations. Implementing further investigations is also a key to dynamically battling the virus mutations. This study involved multiple reactions and reactants, such as ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5Application In Synthesis of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate).
((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5) belongs to tetrahydrofuran derivatives. THF (Tetrahydrofuran) is a stable compound with relatively low boiling point and excellent solvency. THF can also be synthesized by catalytic hydrogenation of furan. This allows certain sugars to be converted to THF via acid-catalyzed digestion to furfural and decarbonylation to furan, although this method is not widely practiced. THF is thus derivable from renewable resources.Application In Synthesis of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem